Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy

@article{Mirzakhani2015AberrantCM,
  title={Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy},
  author={Hooman Mirzakhani and Juli{\"e}t van Dormolen and Karen van der Weide and Henk-Jan Guchelaar and Martijn S. van Noorden and Jesse J. Swen},
  journal={Pharmacogenetics and Genomics},
  year={2015},
  volume={25},
  pages={515–517}
}
We investigated the accumulation of aberrant CYP2D6 genotypes and predicted metabolizer phenotypes (ultrarapid metabolizer, intermediate metabolizer and poor metabolizer) potentially affecting the antidepressant treatment response in depressive patients indicated for electroconvulsive therapy (ECT) compared with patients with a single episode of depression. Seventy-six Dutch White patients with unipolar or bipolar treatment-resistant depression who underwent ECT were genotyped using the… 

References

SHOWING 1-10 OF 10 REFERENCES
Antidepressant Treatment and Altered CYP2D6 Activity: Are Pharmacokinetic Variations Clinically Relevant?
TLDR
This literature review describes the clinical and empirical evidence indicating that alterations in CYP2D6 activity can negatively affect treatment outcomes in patients receiving antidepressant pharmacotherapies that are CYP 2D6 substrates and proposes a strategy to allow for stratification of treatment outcomes by CYP1D6 metabolizer status.
Patients with difficult-to-treat depression do not exhibit an increased frequency of CYP2D6 allele duplication.
TLDR
The CYP2D6 allele frequencies and the predicted phenotype distributions in patients with difficult-to-treat depression were not significantly different to those found in the healthy population of Hungary, suggesting that CYP 2D6 duplication or multiplication does not play a significant role in antidepressant pharmacotherapy failure in this patient sample.
Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.
TLDR
A system that utilizes the CYP2D6 activity score system is proposed to place individuals into a continuum of activity scores - rather than using the traditional poor, intermediate, extensive and ultra-rapid metabolizer categorizations - and directly translating activity scores into clinically actionable recommendations.
The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers
TLDR
The frequencies of CYP1D6 and CYP2C19 allelic variants were in accordance with other European populations, and a gene–dose effect was found for CYP 2C19.
Gender differences in response to differing antidepressant drug classes: two negative studies
TLDR
Examination for gender differences in SSRI and TCA antidepressant response in both retrospective and prospective naturalistic uncontrolled studies, and in subsets of melancholic and non-melancholic depressed subjects failed to find evidence of women having a preferential response to SSRI medication or of men having a superior response to TCA medication.
Antidepressant treatment in bipolar versus unipolar depression.
TLDR
The findings suggest an unfavorable cost/benefit ratio for antidepressant treatment of bipolar depression, and modern antidepressants, in general, did not have lower rates of negative outcomes than tricyclic antidepressants.
Pharmacogenetics: From Bench to Byte— An Update of Guidelines
TLDR
Recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP3A5, and HLA‐B*5701, and factor V Leiden (FVL).
Diagnosis and definition of treatment-resistant depression
  • M. Fava
  • Psychology, Medicine
    Biological Psychiatry
  • 2003
The STAR*D project results: A comprehensive review of findings
TLDR
Prognosis was better at all levels for participants who entered follow-up in remission as opposed to those who entered with response without remission, highlighting the prevalence of treatment-resistant depression and suggesting potential benefit for using more vigorous treatments in the earlier steps.
Older adults with severe, treatment-resistant depression.
TLDR
Collaborative programs, in which primary care clinicians work closely with mental health specialists following a measurement-based treatment-to-target approach, are significantly more effective than typical primary care treatment.